Thursday, 7 July 2016

Siponimod Effective in Reducing Disease Activity in Relapsing=-Remitting MS

Source Neurology Advisor:

Results from the 24-month extension of the phase 2 BOLD study demonstrated no new safety concerns and low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated with siponimod.  Read on.